Antitrust Enforcement 2026 Update: Federal Recalibration, Rising State HSR Regimes, and Deal Strategies

Ms. Browdie is a strategic counselor to many of the world’s most innovative companies, solving clients’ antitrust issues, guiding transactions through merger review and representing clients in government investigations and litigation. Working with clients in a wide range of industries, with a particular focus on life sciences and tech, she has helped secure critical wins in diverse cases and has experience in matters before the U.S. Department of Justice, U.S. Federal Trade Commission (FTC) and state antitrust authorities. Ms. Browdie also counsels clients on a variety of topics, including pricing practices, licensing of intellectual property and other distribution issues. She is an active member of the ABA’s Antitrust Law Section, currently serving as a vice chair on the Health Care and Pharmaceuticals Committee. Ms. Browdie previously held various positions on the Mergers and Acquisitions Committee, the Federal Civil Enforcement Committee and the Presidential Transition Task Force. She was also an editor of the two-volume Antitrust Law Developments (Ninth Edition), the premier antitrust treatise. 

Mr. Lee advises clients on matters involving antitrust, competition, and fair trade within the telecommunications, life sciences, and other high-technology sectors. His experience includes conducting fact finding, drafting, and strategy development for domestic and global antitrust investigations, litigation, and merger review. Mr. Lee also represents clients before the U.S. Department of Justice (DOJ), the Federal Trade Commission (FTC), and other European and Asian regulatory bodies investigating standard essential patent licensing practices and digital platforms. Mr. Lee spent significant time working in South Korea both as in-house counsel to a multinational consumer electronics company and as a foreign legal consultant with one of South Korea’s largest international law firms.